Multiple Sclerosis Drugs Market Report 2025

This Multiple Sclerosis Drugs market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The multiple sclerosis drugs market size has grown strongly in recent years. It will grow from $29.66 billion in 2024 to $31.5 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rising prevalence of multiple sclerosis, unmet medical need, rising investments from pharmaceuticals, growing awareness of multiple sclerosis.

The multiple sclerosis drugs market size is expected to see rapid growth in the next few years. It will grow to $47.97 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to increasing availability of clinical trials, targeted therapy, growing focus on preventive medicine, growing demand for biosimilars, expanding geographical reach, combination therapies. Major trends in the forecast period include immunomodulatory and immunomodulatory drugs, long-acting formulations, patient-centric care, drug innovation, oral and infusion therapies.

Government and non-government organizations contribute significantly to the growth of the multiple sclerosis drugs market. They support various programs and initiatives aimed at improving the quality of life for those affected by multiple sclerosis (MS). An example is the joint investment of $1 million by the government of Alberta and Canada's Department of Economic Development, Trade, and Tourism for the Canadian Prospective Cohort Study on MS (CanProCo). This initiative, supported by multiple organizations, gathered $10 million for research and innovations, uniting nearly 50 MS researchers across disciplines in Canada. Financial backing from these entities drives the expansion of the multiple sclerosis drugs market.

The escalating prevalence of multiple sclerosis stands as a pivotal factor propelling the growth of the multiple sclerosis drug market. MS, an autoimmune disease impacting the central nervous system, requires pharmaceutical intervention for symptom management and disease progression. An article from Pace Hospitals in May 2023 highlighted a global MS patient count of 2.8 million, at a rate of 35.9 per 100,000 individuals, with an annual incidence of 2.1 cases per 100,000 people across 75 reporting countries. The disease typically affects individuals around the age of 32 and shows a higher prevalence among females. This increasing prevalence is set to drive the expansion of the multiple sclerosis drug market.

Companies are intensifying efforts to introduce new products within the multiple sclerosis drug market to cater to the surging demand. Given the lifelong treatment nature of MS, the overall cost of patient care is substantial. To address this, companies are focusing on developing specific drugs tailored for managing multiple sclerosis. Notably, the FDA approved Novartis’ Mayzent (siponimod) and EMD Serono’s Mavenclad (cladribine) for treating relapsing-remitting and active secondary progressive multiple sclerosis. These oral drugs aim to provide more effective treatment options.

Major companies in the multiple sclerosis drugs market are concentrating on developing innovative solutions to enhance treatment effectiveness, improve patient quality of life, and meet the diverse needs of individuals living with multiple sclerosis. Innovative solutions encompass new and creative approaches, products, or technologies aimed at effectively tackling specific challenges or issues. For example, in September 2024, Genentech, a US-based biotechnology firm, announced that the U.S. Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for treating relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo is the first and only subcutaneous injection, administered by healthcare professionals, that is given twice a year and takes about 10 minutes to administer, providing additional treatment options for individuals with MS.

In March 2024, Juvisé Pharmaceuticals, a pharmaceutical company based in France, acquired Actelion Pharmaceuticals Ltd. for an undisclosed sum. This acquisition aims to broaden Juvisé Pharmaceuticals' portfolio and improve patient care by obtaining global commercial rights to Ponvory for treating relapsing multiple sclerosis outside the US and Canada. Actelion Pharmaceuticals Ltd. is a pharmaceutical company located in Switzerland, specializing in the discovery, development, and commercialization of innovative drugs.

Multiple sclerosis drugs, referred to as disease-modifying treatments, aim to halt the progression of disability and the occurrence of disease relapses associated with the condition. These medications work by targeting a protein present on the surface of immune cells, leading to a reduction in the number of white blood cells. This reduction helps prevent relapses in multiple sclerosis by potentially diminishing the white blood cells' tendency to cause nerve injury.

The primary drug classes for multiple sclerosis treatment include immunomodulators, immunosuppressants, interferons, and others. Immunomodulators specifically target pathways involved in treating multiple myeloma and certain other cancers. These drugs can be administered through various routes, including oral and parenteral methods, and are distributed through hospital pharmacies, retail pharmacies, and online platforms.

The multiple sclerosis drugs market research report is one of a series of new reports that provides multiple sclerosis drugs market statistics, including multiple sclerosis drugs industry global market size, regional shares, competitors with a multiple sclerosis drugs market share, detailed multiple sclerosis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the multiple sclerosis drugs industry. This multiple sclerosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Major companies operating in the multiple sclerosis drugs market include Biogen Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Bayer HealthCare LLC, Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Acorda Therapeutics Inc., Actelion Pharmaceuticals Ltd, EMD Serono Inc., AbbVie Inc., Bayer Schering Pharma AG, CinnoVex, Bristol-Myers Squibb Company, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Opexa Therapeutics Inc., Receptos Inc., Synthon Pharmaceuticals Inc., TG Therapeutics Inc., Alexion Pharmaceuticals Inc., Alkermes plc, Amgen Inc., Atara Biotherapeutics Inc., Celgene Corporation, Genzyme Corporation.

North America was the largest region in the global multiple sclerosis drug market in 2024. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple sclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the multiple sclerosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The multiple sclerosis drug market consists of sales of lemtrada, novantrone, ocrevus, and tysabri. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.